Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
How Is The Gastrointestinal Therapeutics Market Size Likely To Evolve From 2025 Through 2034?
The gastrointestinal therapeutics market has demonstrated substantial growth in recent times. This market is projected to expand from $39.99 billion in 2024 to reach $42.30 billion by 2025, exhibiting a compound annual growth rate (CAGR) of 5.8%. Historically, this expansion has been driven by factors such as increased government spending on healthcare, improved rates of early diagnosis, a surge in gut health awareness initiatives, a rise in digestive disorders linked to lifestyle, and the adoption of more multidisciplinary treatment methods.
The gastrointestinal therapeutics market size is anticipated to experience substantial expansion in the coming years, with projections indicating it will reach $52.41 billion by 2029, growing at a compound annual growth rate (CAGR) of 5.5%. This growth throughout the forecast period is primarily driven by factors such as an escalating demand for biologics and targeted therapies, the increasing adoption of personalized medicine, a rising patient preference for combination therapies, an intensified focus on microbiome-targeted therapeutics, and the growing incidence of antibiotic-associated gastrointestinal complications. Significant trends expected during this period include the integration of advanced technology into endoscopic devices, the development of microbiome-based therapies, the incorporation of digital health and remote monitoring solutions, the utilization of multi-omics data in therapy development, and ongoing innovations in acid suppression treatments.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25768&type=smp
Which Major Market Drivers Are Shaping The Future Of The Gastrointestinal Therapeutics Market?
The increasing incidence of inflammatory bowel diseases is projected to stimulate the growth of the gastrointestinal therapeutics market moving forward. Inflammatory bowel disease (IBD) is a long-term condition characterized by inflammation of the digestive tract, primarily involving Crohn’s disease and ulcerative colitis. The rise in inflammatory bowel diseases is attributed to genetic susceptibility, which causes an abnormal immune response to gut microbes. Gastrointestinal therapeutics aid in the management and treatment of bowel diseases by targeting underlying inflammation, regulating digestive functions, and alleviating associated symptoms to enhance patient outcomes. For instance, in December 2023, according to the IBD Registry, a UK-based non-profit organization, more than 5,300 individuals with inflammatory bowel diseases (IBD) were registered in 2023, indicating an increase of over 3,000 members from 2022. Consequently, the escalating occurrence of inflammatory bowel diseases is propelling the expansion of the gastrointestinal therapeutics market.
What Are The Primary Types Of Segments Analyzed In The Gastrointestinal Therapeutics Market?
The gastrointestinal therapeutics market covered in this report is segmented –
1) By Product: Over-The-Counter Gastrointestinal Therapeutics, Prescription-Based Gastrointestinal Therapeutics
2) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration
3) By Application: Inflammatory Bowel Disease, Gastroesophageal Reflux Disease, Peptic Ulcer Disease, Irritable Bowel Syndrome, Other Applications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Laboratories, Other End-Users
Subsegments:
1) By Over-The-Counter Gastrointestinal Therapeutics: Antacids, Laxatives, Anti-Diarrheal Agents, Digestive Enzymes, Probiotics, H2-Receptor Antagonists, Simethicone Products
2) By Prescription-Based Gastrointestinal Therapeutics: Proton Pump Inhibitors, Antibiotics For H. pylori, Aminosalicylates, Biologics, Corticosteroids, Immunosuppressants, Antiemetics
How Are Emerging Market Trends Shaping The Gastrointestinal Therapeutics Industry Landscape?
Leading companies in the gastrointestinal therapeutics market are prioritizing the creation of innovative therapies, such as sustained-release (SR) fixed-dose combination capsules, to enhance patient adherence and improve treatment efficacy. These sustained-release (SR) fixed-dose combination capsules are oral medications engineered to progressively release multiple active ingredients over time, thus maintaining consistent drug levels and minimizing dosing frequency. For example, in June 2024, Akums Drugs and Pharmaceuticals Limited, an India-based pharmaceutical preparation manufacturing company, introduced rabeprazole + levosulpiride SR capsules for managing gastrointestinal disorders in India. This formulation unites rabeprazole, a proton pump inhibitor that reduces stomach acid, with levosulpiride, a prokinetic agent that boosts gut motility. Together, they provide effective relief from symptoms including heartburn, acid reflux, bloating, and indigestion. This combination is broadly prescribed for the treatment of gastroesophageal reflux disease, peptic ulcers, and other related gastrointestinal (GI) conditions.
Which Leading Players Are Enhancing Their Gastrointestinal Therapeutics Market Presence Worldwide?
Major companies operating in the gastrointestinal therapeutics market are Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited., Boehringer Ingelheim International GmbH, Otsuka Holdings Co. Ltd., Daiichi Sankyo Company Limited., Bausch Health Companies Inc, Olympus Corporation, UCB S.A., Eisai Co. Ltd., Aurobindo Pharma Limited., Dr. Reddy’s Laboratories Limited., Ironwood Pharmaceuticals Inc, Salix Pharmaceuticals Ltd., Ferring Pharmaceuticals A/S, Jubilant Pharma Limited., Sebela Pharmaceuticals Inc, Cosmo Pharmaceuticals N.V., Tillotts Pharma AG, Mitsubishi Tanabe Pharma Corporation
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/gastrointestinal-therapeutics-global-market-report
Which Regional Markets Are Contributing Most To The Gastrointestinal Therapeutics Industry Expansion?
North America was the largest region in the gastrointestinal therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Gastrointestinal Therapeutics Market Report:
https://www.thebusinessresearchcompany.com/customise?id=25768&type=smp
Browse Through More Reports Similar to the Global Gastrointestinal Therapeutics Market 2025, By The Business Research Company
Gastrointestinal Drugs Global Market 2025
https://www.thebusinessresearchcompany.com/report/gastrointestinal-drugs-global-market
Gastroparesis Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report
Digestive And Intestinal Remedies Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model